Skip to main content
. 2022 Mar 31;399(10332):1313–1321. doi: 10.1016/S0140-6736(22)00151-9

Table 4.

Analysis of neutralising antibodies (PRNT50; immunogenicity population)

ZyCoV-D (n=50) Placebo (n=47)
Day 0
GMT (95% CI) 5·00 (5·00–5·00) 5·00 (5·00–5·00)
Day 56
GMT (95% CI) 83·10 (50·70–136·20) 28·64 (15·32–53·53)
GMFR (95% CI) 16·62 (10·14–27·24) 5·73 (3·06–10·71)
Day 84
GMT (95% CI) 133·39 (86·88–204·81) 26·99 (14·48–50·32)
GMFR (95% CI) 26·68 (17·38–40·96) 5·40 (2·90–10·06)

GMT=geometric mean titre. GMFR=geometric mean fold rise.